IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study

Suppiah, Vijayaprakash; Gaudieri, Silvana; Armstrong, Nicola J; O'Connor, Kate S; Berg, Thomas; Weltman, Martin; Abate, Maria Lorena; Spengler, Ulrich; Bassendine, Margaret; Dore, Gregory J; Irving, William L; Powell, Elizabeth; Hellard, Margaret; Riordan, Stephen; Matthews, Gail; Sheridan, David; Nattermann, Jacob; Smedile, Antonina; Müller, Tobias; Hammond, Emma; Dunn, David; Negro, Francesco; Bochud, Pierre-Yves; Mallal, Simon; Ahlenstiel, Golo; Stewart, Graeme J; George, Jacob; Booth, David R

doi:10.1371/journal.pmed.1001092

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study
Authors		Suppiah, Vijayaprakash Gaudieri, Silvana Armstrong, Nicola J O'Connor, Kate S Berg, Thomas Weltman, Martin Abate, Maria Lorena Spengler, Ulrich Bassendine, Margaret Dore, Gregory J Irving, William L Powell, Elizabeth Hellard, Margaret Riordan, Stephen Matthews, Gail Sheridan, David Nattermann, Jacob Smedile, Antonina Müller, Tobias Hammond, Emma Dunn, David Negro, Francesco Bochud, Pierre-Yves Mallal, Simon Ahlenstiel, Golo Stewart, Graeme J George, Jacob Booth, David R show all authors [1 - 28]
Published in		PLOS Medicine. 2011, vol. 8, no. 9, p. e1001092
Abstract		To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIFN/R). Viral clearance is achieved in 40%-50% of patients. Interleukin 28B (IL28B) genotype predicts treatment-induced and spontaneous clearance. To improve the predictive value of this genotype, we studied the combined effect of variants of IL28B with human leukocyte antigen C (HLA-C), and its ligands the killer immunoglobulin-like receptors (KIR), which have previously been implicated in HCV viral control.
Keywords		Adult — Alleles — Antiviral Agents/therapeutic use — Case-Control Studies — Cohort Studies — Cross-Sectional Studies — Drug Therapy, Combination — European Continental Ancestry Group — Female — Genotype — HLA-C Antigens/genetics — Hepacivirus/immunology/pathogenicity — Hepatitis C, Chronic/genetics/immunology/therapy/virology — Humans — Interferon-alpha/therapeutic use — Interleukins/genetics — Killer Cells, Natural/immunology — Male — Middle Aged — Odds Ratio — Pharmacogenetics/methods — Polymorphism, Single Nucleotide — Predictive Value of Tests — RNA, Viral/analysis — Receptors, KIR/genetics — Receptors, KIR2DL3/genetics — Ribavirin/therapeutic use — Treatment Outcome — Viral Load
Identifiers		DOI: 10.1371/journal.pmed.1001092 PMID: 21931540
Full text		Article (Published version) (180 Kb) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie
Research group		Etudes et traitement de l'hépatite C et B (554)
Citation (ISO format)		SUPPIAH, Vijayaprakash et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. In: PLOS Medicine, 2011, vol. 8, n° 9, p. e1001092. doi: 10.1371/journal.pmed.1001092 https://archive-ouverte.unige.ch/unige:25521